Benitec Biopharma Inc.

Benitec Biopharma Inc. is a Delaware corporation focused on developing novel genetic medicines. The company's proprietary platform, "Silence and Replace" DNA-directed RNA interference, combines RNA interference (RNAi) with gene therapy. This platform creates medicines designed to simultaneously silence disease-causing genes and deliver wildtype replacement genes after a single administration of the therapeutic construct. Benitec Biopharma Inc. is listed on the Nasdaq Capital Market under the symbol "BNTC". The company's fiscal year ends on June 30. During the fiscal year ended June 30, 2021, the company completed an organizational restructuring to create a more efficient structure as it transitioned operations to the United States. Benitec Biopharma Inc. is the parent entity of several subsidiaries, including Benitec Biopharma Proprietary Limited (formerly Benitec Biopharma Limited), which was incorporated in Australia in 1995. The company's wholly owned subsidiaries include Benitec Biopharma Proprietary Limited and Benitec Australia Proprietary Limited in Australia; Benitec Limited in the United Kingdom; and Benitec, Inc., Benitec LLC, RNAi Therapeutics, Inc., Tacere Therapeutics, Inc., and Benitec IP Holdings, Inc. in the USA. Aside from Benitec Biopharma Proprietary Limited, the international subsidiaries are dormant.